dihexa renal Peptide Therapy Dihexa: Mechanism, Effects & Research

Data Availability Statement Data sharing not applicable.

It contains BPC (Body Protection Compound) in the form of short-chain amino acids that promote soft tissue recovery, digestive balance, and neurological support

This process is defined as active immunotherapy as the hosts immune system is either de novo activated or restimulated to mount an effective, tumor-specific immune reaction that may ultimately lead to tu-mor regression

Some phenotypes plausibly need a slower-than-label climb: lighter bodies (higher exposure per milligram), a history of severe GLP-1 gut intolerance, a high baseline heart rate, or a lean, low-reserve build

Disclosure of interest: Anastasios Mavridis: Nothing to Disclose, Adam Viktorisson: Nothing to Disclose, Bjrn Eliasson: Nothing to Disclose, Mia von Euler: Nothing to Disclose, Katharina S Sunnerhagen: Nothing to Disclose Poster Session II - RISK FACTORS - PRIMARY AND SECONDAR PREVENTION 05.00 - RISK FACTORS AND PREVENTION (PRIMARY AND SECONDARY) - 05.04 - STROKE COMPLICATIONS P999 - ESOC25-160 PREDICTORS OF 90-DAY OUTCOMES AND HEMORRHAGIC RISK AFTER ENDOVASCULAR THROMBECTOMY WITH STENT RELEASE IN PATIENTS WITH ACUTE CAROTID ARTERY ATHEROSCLEROTIC ISCHEMIC STROKE Gaia Mignani 1 , Marta Del Chicca 1 , Nicola Giannini 1 , Marco Baldini 1 , Roberto D'agliano 1 , Alessandro Grigolini 2 , Giacomo Petrucci 2 , Filippo Baldacci 1 , Mirco Cosottini 2 1 Neurological Clinic, University of Pisa, Pisa, Italy, 2 Neuroradiology Unit, University of Pisa, Pisa, Italy Background and Aims: To investigate clinical and procedural factors associated with the 90-day modified Rankin Scale (mRS) and symptomatic intracranial hemorrhage (sICH) at 6 and 12 hours after endovascular thrombectomy (EVT) with carotid stent release